SAT0692 PREDICTORS AND PERSISTENCE OF UNACCEPTABLE PAIN DURING THE FIRST YEAR OF RHEUMATOID ARTHRITIS IN SWEDEN
Background: Pain is a dominant symptom in rheumatoid arthritis (RA). Objectives: Investigate unacceptable pain (VAS-pain ≥40) during the first year of the disease and whether it can be predicted from baseline disease characteristics.
Methods:
The cohort included all incident RA cases from the Swedish populationbased case-control Epidemiological Investigation of Rheumatoid Arthritis study (EIRA), who also were in the Swedish Rheumatology Register. Unacceptable pain was defined as scoring 40 mm or above on the pain visual analog scale (VAS) (i.e. not reaching the patient acceptable symptom state (PASS) (1)), and the proportion of patients going in and out of PASS was traced over the first year. Association between baseline parameters, divided into quartiles, and unacceptable pain at one year was assessed using modified Poisson regression and expressed as risk ratios with 95% confidence intervals (95% CI), adjusted for sex and age at diagnosis. Results: A total of 2808 patients were included in the study and 33.8% of the patients presented with PASS (i.e.VAS pain below 40) at inclusion. If a patient had PASS at any given visit, there was over 70% chance that the patient remained in PASS at the following visit. The most common PASS pattern (25.6%), was to present with unacceptable pain, reach PASS at the 3 month visit, and then remain in PASS. However, one year after diagnosis, only two thirds of the patients had PASS. Higher disability (measured as HAQ) at baseline was significantly and independently associated with an increased risk for unacceptable pain at one year (for the highest quartile of HAQ; RR=1. Background: Serum uric acid levels increase in postmenopausal women but decrease when hormone replacement therapy (HRT) is administered. However, no study has evaluated the effects of different types of HRT on serum uric acid levels. Objectives: We examined whether estrogen monotherapy, estrogen-progestogen combination therapy, and tibolone use affected serum uric acid levels in this population.
We performed a retrospective case-control study of postmenopausal women. From 2005 to 2015, postmenopausal women measured serum uric acid levels more than twice were included. Patients were grouped according to HRT regimen: estrogen monotherapy, estrogen-progestogen combination therapy, or tibolone. The control group did not receive HRT. Differences in serum uric acid levels were examined in each group. Our analysis was adjusted to accommodate different follow-up intervals for individual patients. Multiple variables were adjusted using the Tukey-Kramer method. Age, body mass index, hypertension, diabetes mellitus, dyslipidemia, alcohol consumption, smoking status, and co-medications were also adjusted. Results: In the control group, the serum uric acid level increased to 0.86±0.27 mg/dL (least squares mean ± standard error). In comparison, after adjusting for multiple variables, the serum uric levels in the estrogen-progestogen combination 
